Wells Fargo notes that Glaukos (GKOS) has announced FDA approval of its repeat dosing label for iDose, in line with the firm’s expectations. Label appears broad though with some corneal-safety limits. Overall, Wells views this as supportive of the long-term iDose annuity model. The firm has an Overweight rating on the shares with a price target of $122.
Claim 50% Off TipRanks Premium
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GKOS:
Disclaimer & DisclosureReport an Issue
Glaukos announces FDA approval of iDose TR NDA labeling supplement
Glaukos price target raised to $160 from $115 at Stifel
Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors
Glaukos falls -8.5%
Video: Wells Fargo dips as big bank earnings continue
